Diabetes Drugs Show Promise for Stroke Survivors, but Guidelines Lag Behind

Two drug classes born as diabetes therapies are quietly reshaping cardiovascular medicine, and a group of European stroke specialists argues that stroke survivors may be missing out. In a commentary published in Frontiers in Stroke, researchers from Norway, Denmark and the United Kingdom review the evidence for sodium–glucose cotransporter-2 inhibitors and incretin-based therapies, concluding that many people seen in stroke services could be eligible for these cardiometabolic drugs even though neither class appears in current secondary stroke prevention guidelines.

The argument rests on a simple clinical reality. Stroke predominantly affects older adults, and the comprehensive work-up that follows an acute event frequently uncovers previously undiagnosed cardiovascular comorbidities. Approximately one in five individuals presenting with acute stroke has type 2 diabetes, whether pre-existing or newly identified, and impaired kidney function and heart failure are also common among stroke survivors. Each of these conditions now has guideline-supported indications for the newer drug classes, which means a large share of patients treated in stroke units could benefit from therapies that stroke guidelines have yet to embrace.

The story of these agents begins with a regulatory mandate. Because some older antidiabetic drugs were linked to adverse cardiovascular outcomes, the U.S. Food and Drug Administration required in 2008 that all new glucose-lowering agents demonstrate cardiovascular safety in dedicated outcomes trials. That requirement produced an unexpected discovery: certain drugs not only met the safety bar but actively reduced cardiovascular events, with additional benefits for heart failure and chronic kidney disease. The therapeutic paradigm shifted, positioning these molecules as cardiometabolic agents with disease-modifying effects that extend far beyond glycemic control.

SGLT2 inhibitors work by blocking the sodium–glucose cotransporter 2 in the proximal renal tubules, increasing urinary excretion of glucose and water. The result is modest reductions in blood glucose, blood pressure and body weight, and the drugs are generally well tolerated, though they are not recommended when the glomerular filtration rate falls below 20 mL/min/1.73 m² and they carry an increased risk of ketoacidosis and genital infections. Despite only limited reductions in HbA1c, the class significantly reduces cardiovascular events and improves survival in patients with type 2 diabetes at high cardiovascular risk, with benefits consistent across multiple agents, supporting a class-wide effect.

The cardiovascular benefit of SGLT2 inhibitors is driven mainly by reductions in cardiovascular mortality and heart failure hospitalizations, with a more modest effect on atherosclerotic cardiac events. Subsequent trials showed that the drugs reduce heart failure-related hospitalizations regardless of whether ejection fraction is reduced or preserved, and in chronic kidney disease they slow progression and preserve kidney function even in the absence of diabetes. Heart failure and nephrology guidelines now recommend SGLT2 inhibitors as first-line medical treatment for chronic kidney disease with albuminuria or heart failure, irrespective of diabetes status. The recently updated NICE guidelines in the United Kingdom go further, recommending the class as first-line therapy alongside metformin in type 2 diabetes.

Importantly, current evidence does not support a clear reduction in recurrent stroke with SGLT2 inhibitor therapy. That gap separates the class from incretin-based therapies, which have shown a more direct effect on cerebrovascular risk. A meta-analysis of GLP-1 receptor agonists confirmed a reduction in stroke risk in people with type 2 diabetes, with a hazard ratio of 0.83, and a smaller effect on myocardial infarction. In patients with type 2 diabetes, the cardiovascular benefit is reflected in an approximately 14 percent reduction in the composite major adverse cardiovascular event endpoint of myocardial infarction, stroke and cardiovascular death, corresponding to a number needed to treat of 65 to avoid one event over 2.1 years.

The individual trial data are striking. Semaglutide reduced nonfatal stroke with a hazard ratio of 0.61 and showed a trend toward reduction in nonfatal myocardial infarction, though it had no effect on cardiovascular death. A recent small randomized study of patients with type 2 diabetes following minor stroke or high-risk transient ischemic attack observed a reduction in 90-day recurrent stroke with liraglutide. Beyond glycemic effects, incretin-based therapies produce substantial weight loss that appears to be a class effect, with greater reductions from injectable than oral formulations, and recent American Gastroenterological Association guidelines recommend incretins alongside lifestyle intervention for adults with obesity regardless of diabetes status.

The mechanisms underlying the stroke risk reduction remain unclear, but potential pathways include effects on platelet aggregation, endothelial function and overall cardiometabolic health. The interplay among obesity, type 2 diabetes, chronic kidney disease, heart failure and cardiovascular disease has also prompted the emergence of the concept of cardiovascular–kidney–metabolic syndrome, with a new 2026 guideline from American heart, kidney and diabetes organizations providing Class 1 recommendations for both drug classes in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists has not been evaluated in dedicated randomized trials, but a meta-analysis of current evidence suggests it is safe and effective, though use remains limited, likely due to high costs.

On practical grounds, the commentary authors note that both drug classes can usually be initiated during the hospital stay for acute stroke once the patient is clinically stable. SGLT2 inhibitors should be started after assessment of renal function and volume status, with counseling on the risk of genital infections, dehydration and sick-day management, while GLP-1 receptor agonists should be initiated at a low dose and titrated slowly to improve gastrointestinal tolerability. Early outpatient follow-up is recommended to assess adherence and tolerability and to adjust concomitant medications as needed.

The authors conclude that the diagnostic work-up following an acute stroke should include screening for potentially modifiable risk factors, including type 2 diabetes, chronic kidney disease, heart failure and obesity, and that patients identified with these conditions should be managed in accordance with current evidence-based guidelines, including consideration of SGLT2 inhibitors and incretin-based therapies when appropriate. Clinicians should carefully weigh competing risks, particularly the substantial risk of all-cause mortality following stroke, alongside patient preferences, and clear pathways are needed for responsibility, titration and follow-up. Additional studies are required to assess whether these agents reduce stroke incidence, recurrence or severity, and to identify the specific patient subgroups and care settings in which they confer benefit, but the message is clear: stroke practice may need to evolve ahead of guideline updates to optimize care and improve long-term outcomes.

Subject of Research: Cardiometabolic drugs after stroke

Article Title: Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?

Article References: Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?. (n.d.). https://doi.org/10.3389/fstro.2026.1918465

Image Credits: AI Generated

DOI: 10.3389/fstro.2026.1918465

Keywords: stroke, SGLT2 inhibitors, GLP-1 receptor agonists, secondary prevention, type 2 diabetes, heart failure, chronic kidney disease, obesity, cardiovascular-kidney-metabolic syndrome, semaglutide, stroke guidelines, clinical practice